



Prism Medico And Pharmacy Limited

Reg. Office : D-118, Industrial Area, Phase VII, Mohali-160055

Tel: 0172-5020762

Email : investorgrievancewmcl@gmail.com

www.prismmedico.com

Date: 02/12/2020

<p>To, Department of Corporate Services, BSE LIMITED P. J. Towers, Dalal Street, Mumbai - 400 001</p>	<p>To, Listing Department, Metropolitan Stock Exchange of India Ltd. (MSE) Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai - 400 098, India. ISIN : INE730E01016</p>
<p>Scrip Code: 512217</p>	

Sub: Reply to Observations: Discrepancies in Standalone Financial Results: Financial Result submitted in PDF file is not as per IND-AS Format . Submit revised Financial results in PDF file on BSE Listing centre in accordance with Schedule III format of Companies Act, 2013 and Cash Flow Statement for Standalone Results not received in PDF.

Dear Sir,

This is with reference to your e-mail dated 27th November 2020 regarding Quarterly Financial Results for 30th September 2020, kindly note that the exchange has observed the above mentioned discrepancies.


In this regards, we are enclosing herewith Financial results for the quarter ended 30th September 2020 as per IND-AS format and Cash Flow statement.

You are requested to kindly take the same on record.

Thanking You,

Yours Truly,

For PRISM MEDICO & PHARMACY LIMITED


Sudhanshu Srivastav

Director

DIN: 08242441

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2020 (IN LAKHS)

PARTICULARS	Quarter Ended (Unaudited)		Period Ended (UnAudited)	Period Ended (UnAudited)	Year Ended (Audited)	
	30.09.2020	30.06.2020				30.09.2019
INCOME FROM OPERATIONS						
A Net Sales/ Income From Operations	637.77	0.00	659.73	637.77	1260.89	2689.01
B Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
TOTAL INCOME FROM OPERATIONS (NET)	637.77	0.00	659.73	637.77	1260.89	2689.01
2 EXPENSES:						
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of Stock-In-Trade	597.98	0.00	540.56	597.98	1117.21	2569.70
Change In Inventories	0.00	0.00	91.60	0.00	88.43	91.38
Employee Benefit Expenses	0.42	0.00	5.02	0.42	8.77	21.90
Depreciation	0.31	0.30	0.41	0.61	0.85	1.76
Other expenses	1.35	4.61	1.10	5.96	6.98	11.05
TOTAL EXPENSES	600.06	4.91	638.69	604.97	1222.24	2695.79
PROFIT / (LOSS) FROM OPERATION BEFORE OTHER INCOME, FINANCE COST AND EXCEPTIONAL ITEMS (1-2)	37.71	-4.91	21.04	32.80	38.65	-6.78
3 Other Income	0.00	0.00	0.00	0.00	0.00	0.00
PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3 + 4)	37.71	-4.91	21.04	32.80	38.65	-6.78
6 Finance Cost	0.00	0.00	0.02	0.00	0.02	0.02
PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5 + 6)	37.71	-4.91	21.02	32.80	38.63	-6.80
8 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7 + 8)	37.71	-4.91	21.02	32.80	38.63	-6.80
0 TAX EXPENSE:						
(1) Current Tax	9.80	0.00	4.10	9.80	7.49	0.00
(2) Deferred Tax	0.0089	0.0089	0.00	0.02	0.42	1.78
(3) MAT Credit	0.00	0.00	5.36	0.00	5.36	0.00

1	NET PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9+10)	27.90	-4.92	22.28	22.98	36.08	-5.02
2	Extraordinary Items (Net of Tax Expense Lakhs)	0.00	0.00	0.00	0.00	0.00	0.00
3	NET PROFIT / (LOSS) FOR THE PERIOD (11 + 12)	27.90	-4.92	22.28	22.98	36.08	-5.02
4	Share of Profit / (loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00
5	Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00
6	NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) *	27.90	-4.92	22.28	22.98	36.08	-5.02
7	Paid-up equity share capital (Face Value of the Share shall be indicated)	606.34	606.34	606.34	606.34	606.34	606.34
8	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	722.21	694.31	748.96	722.21	748.96	699.25
9	Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):						
	(1) BASIC	0.05	-0.01	0.04	0.04	0.06	-0.01
	(2) DILUTED	0.05	-0.01	0.04	0.04	0.06	-0.01
	Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):						
	(1) BASIC	0.05	-0.01	0.04	0.04	0.06	-0.01
	(2) DILUTED	0.05	-0.01	0.04	0.04	0.06	-0.01

* Applicable in the case of consolidated results.

Notes:

- The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10/11/2020.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.

3. The company is having single segment in accordance with IND AS 108 "operating segments", and therefore segment reporting is not applicable to the Company.

Place : Mohali

Date: 10/11/2020

FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.



Sudhanshu Srivastav

Director

DIN: 08242441

PRISM MEDICO AND PHARMACY LIMITED

Unaudited Standalone Cash flow statement

(Amount Rs. In Lakhs)


Particulars	For the half year ended	For the half year ended
	30th Sept 2020	30th Sept 2019
A. Cash flow from operating activities		
Profit/(Loss) before tax	32.80	38.63
Adjustments for:		
Depreciation and amortisation	0.61	0.85
Other Adjustment	(0.59)	
Operating profit before working capital changes	32.82	39.48
Adjustments for movement in:		
Trade payables	3.36	240.43
Provisions and other liabilities	(6.83)	(0.25)
Trade receivables	(32.05)	(453.68)
Loans and advances and other assets	2.45	86.20
Inventories	-	88.43
Cash generated from/(used in) operations	(0.25)	0.59
Income taxes paid (including taxes deducted at source)		-
Net cash generated from/(used in) operating activities	(0.25)	0.59
B Cash flow from investing activities :		
Purchase of fixed assets	-	-
Movement in Investments	-	-
Net cash (used in) investing activities	-	-
C Cash flow from financing activities		
Movement in long-term borrowings	-	-
Movement in short-term borrowings	-	-
Net cash (used in)/generated from financing activities	-	-
Net increase in cash and cash equivalents (A+B+C)	(0.25)	0.59
Cash and cash equivalents as at 1st April	11.18	11.76
Cash and cash equivalents as at 30th September	10.93	12.35

Notes:

- a) The above cash flow statement has been prepared under the "Indirect Method" as set out in Accounting Standard 3 (AS-3) on "Cash flow statements" as specified under section 133 of Companies Act, 2013 read with Rule 7 of the
- b) Negative figures have been shown in brackets.

This is the cash flow statement referred to in our report of even date.

FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.


Sudhanshu Srivastava
Director

Place : Mohali

Date : 10/11/2020